Press release
Zika Virus Infection Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Curious about the latest updates in the Zika Virus Infection Pipeline? Click here to explore the therapies and trials making headlines @ Zika Virus Infection Pipeline Outlook Report [https://www.delveinsight.com/sample-request/zika-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Zika Virus Infection Pipeline Report
* On 25 September 2025, ModernaTX Inc . announced a clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
* DelveInsight's Zika Virus Infection Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Zika Virus Infection treatment.
* The leading Zika Virus Infection Companies such as Cerus Corporation, ModernaTX Inc. and others.
* Promising Zika Virus Infection Pipeline Therapies such as mRNA-1893, GLS-5700 and others.
Want to know which companies are leading innovation in Zika Virus Infection? Dive into the full pipeline insights @ Zika Virus Infection Clinical Trials Assessment [https://www.delveinsight.com/sample-request/zika-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Zika Virus Infection Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Zika Virus Infection Pipeline Report also highlights the unmet needs with respect to the Zika Virus Infection.
Zika Virus Infection Overview
Zika fever is a mosquito-borne viral disease caused by Zika virus (ZIKV), consisting of mild fever, rash (mostly maculo-papular), headaches, arthralgia, myalgia, asthenia, and non-purulent conjunctivitis, occurring about two to seven days after the mosquito vector bite. Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus).
Zika Virus Infection Emerging Drugs Profile
* mRNA-1893: Moderna Therapeutics
mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. The drug is in Phase II clinical studies for the treatment of Zika Virus Infection. In August 2019, Moderna announced that the US FDA has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) for the prevention of Zika virus infection in healthy adults.
* GLS-5700: GeneOne Life Science
GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika Virus Infection and is currently in Phase I stage of development.
If you're tracking ongoing Zika Virus Infection Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Zika Virus Infection Treatment Drugs [https://www.delveinsight.com/sample-request/zika-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Zika Virus Infection Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Zika Virus Infection with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Zika Virus Infection Treatment.
* Zika Virus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Zika Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Zika Virus Infection market.
Zika Virus Infection Companies
Cerus Corporation, ModernaTX Inc. and others.
Zika Virus Infection Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Zika Virus Infection Products have been categorized under various Molecule types such as,
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
From emerging drug candidates to competitive intelligence, the Zika Virus Infection Pipeline Report covers it all - check it out now @ Zika Virus Infection Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/zika-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Zika Virus Infection Pipeline Report
* Coverage- Global
* Zika Virus Infection Companies- Cerus Corporation, ModernaTX Inc. and others.
* Zika Virus Infection Pipeline Therapies- mRNA-1893, GLS-5700 and others.
* Zika Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Zika Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Zika Virus Infection Treatment landscape in this detailed analysis @ Zika Virus Infection Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/zika-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Zika Virus Infection: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Zika Virus Infection - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* mRNA 1893: Moderna Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Tyzivumab: Tychan/WuXi Biologics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EMX 001: Emergex Vaccines
* Drug profiles in the detailed report.....
* Inactive Products
* Zika Virus Infection Key Companies
* Zika Virus Infection Key Products
* Zika Virus Infection- Unmet Needs
* Zika Virus Infection- Market Drivers and Barriers
* Zika Virus Infection- Future Perspectives and Conclusion
* Zika Virus Infection Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=zika-virus-infection-pipeline-drugs-report-2025-emerging-therapies-clinical-developments-and-drug-insights-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/zika-virus-infection-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Zika Virus Infection Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight here
News-ID: 4216934 • Views: …
More Releases from ABNewswire
Chikungunya Pipeline Drugs Report 2025: Emerging Therapies, Clinical Development …
DelveInsight's "Chikungunya Pipeline Insight 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Chikungunya pipeline landscape. It covers the Chikungunya Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chikungunya Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Chikungunya Pipeline?…
Acute Lymphocytic Leukemia Pipeline Outlook Report 2025: Emerging Therapies, Cli …
DelveInsight's, "Acute Lymphocytic Leukemia Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Exploring the Role of Business Loans in Building Entrepreneurial Success
In most cases, expanding an enterprise entails more than good ideas and labor. It requires capital to seize new opportunities, grow or to survive through difficult periods. The process of learning how to acquire the appropriate business loan to grow your business can mean the difference between achieving your objectives and stagnating. Having an appropriate funding partner will enable you to take your business to the next level in the…
Diarrhea Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, …
DelveInsight's "Diarrhea Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diarrhea pipeline landscape. It covers the Diarrhea Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diarrhea Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Diarrhea Pipeline?…
More Releases for Zika
Zika Virus Vaccines Market 2022 | High rate of incidence of active Zika virus in …
Zika Virus Vaccines Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $18,697 million by 2022, registering a CAGR of 5.2% during the forecast period 2017-2022.Key opportunities include the need for vaccines for immunization & prevention of further spread of Zika virus infection and for treatment of Zika-linked birth defects.
Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/1817
The outbreak of Zika virus infection in Latin…
Zika Vaccines Market Size, Share, Development by 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Zika Vaccines market.
Click to view the full report TOC, figure and tables:
https://www.marketresearchreportstore.com/reports/212025/global-zika-vaccines-market
Global Zika Vaccines Market: Forecast by Type / Application / Region
According to this study, over the next five years the Zika Vaccines market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from…
Global Zika Virus Market Research Report 2017
Qyresearchreports include new market research report "Global Zika Virus Market Research Report 2017" to its huge collection of research reports.
The global market for Zika Virus has been marked on several factors that are on the verge or have already impacted the growth of the market in several contexts. The report further pronounces different statistics and data pertaining to the global Zika Virus market. The core aim of the report is…
Global Zika Virus Market Research Report 2017
The Global Zika Virus 2017 Market Research Report is a professional and in-depth study on the current state of the Zika Virus industry.
Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Zika Virus market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status.
Secondly, development policies and plans are discussed as well…
Zika Vaccines Market - Global Industry Insights 2025
Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus. This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also be transmitted through blood transfusion, sexual contact or from infected pregnant women to the fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only 1 in 4 people with zika infection are prone to develop…
Zika Virus Consumption 2016 Market Research Report
Qyresearchreports include new market research report Global Zika Virus Consumption 2016 Market Research Report to its huge collection of research reports.
This report is a descriptive and analytical dissemination of information in the Zika Virus, for those associated with it or those who wish to enter the market in the immediate future. The report provides – within its predetermined forecast period – the latest installment of this stream of research reports.…
